-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Scopolamine Hydrobromide in Motion Sickness
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Scopolamine Hydrobromide in Motion Sickness Drug Details: Scopolamine hydrobromide is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Entolimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Entolimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Entolimod in Radiation Toxicity (Radiation Sickness, Acute Radiation...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avoplacel in Radiation Toxicity (Radiation Sickness, Acute Radiation...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNT-101 in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNT-101 in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNT-101 in Radiation Toxicity (Radiation Sickness, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tradipitant in Functional (Non Ulcer) Dyspepsia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tradipitant in Functional (Non Ulcer) Dyspepsia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tradipitant in Functional (Non Ulcer) Dyspepsia Drug Details: Tradipitant (VLY-686,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tradipitant in Gastroparesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tradipitant in Gastroparesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tradipitant in Gastroparesis Drug Details: Tradipitant (VLY-686, LY-686017) is under development for the...
-
Product Insights
Pulmonary Radiation Toxicity – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Radiation Toxicity - Drugs In Development, 2023’, provides an overview of the Pulmonary Radiation Toxicity pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Radiation Toxicity , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...
-
Product Insights
Radiation Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Injury - Drugs In Development, 2023’, provides an overview of the Radiation Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Tay-Sachs Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Tay-Sachs Disease - Drugs In Development, 2023’, provides an overview of the Tay-Sachs Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tay-Sachs Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gastrointestinal Radiation Toxicity – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Radiation Toxicity - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Radiation Toxicity pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Radiation Toxicity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...